Kelly Lang-Sheppard, APRN
Clinical Nurse Specialist · Oklahoma City, OKNPI 1972940708
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 177 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,964, 5.2 times the $377 reported in 2021. Among clinical nurse specialist clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 177 payments — averaging $26.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$732
- Lilly USA, LLC$357
- Xeris Pharmaceuticals, Inc.$355
- Tandem Diabetes Care, Inc.$324
- Madrigal Pharmaceuticals$321
- Dexcom, Inc.$319
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,58798%
- Education$431%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 13 | $732 |
| Lilly USA, LLC | 21 | $357 |
| Xeris Pharmaceuticals, Inc. | 15 | $355 |
| Tandem Diabetes Care, Inc. | 12 | $324 |
| Madrigal Pharmaceuticals | 7 | $321 |
| Dexcom, Inc. | 17 | $319 |
| Sanofi-aventis U.S. LLC | 9 | $291 |
| Insulet Corporation | 14 | $289 |
| Corcept Therapeutics | 11 | $241 |
| Mannkind Corporation | 6 | $237 |
| Medtronic | 4 | $229 |
| Ascensia Diabetes Care US Inc. | 6 | $168 |
| Boehringer Ingelheim | 7 | $130 |
| BETA Bionics, Inc. | 7 | $129 |
| Sequel Med Tech, LLC | 5 | $113 |
| Amgen | 6 | $111 |
| Novo Nordisk | 4 | $67 |
| Cequr Corporation | 2 | $49 |
| AstraZeneca(2 entities) | 2 | $38 |
| AbbVie | 2 | $36 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Globus Medical | 1 | $27 |
| Astellas Pharma US Inc | 1 | $25 |
| Almatica Pharma LLC | 1 | $22 |
| Acella Pharmaceuticals, LLC | 1 | $19 |
| Bayer | 1 | $19 |
| IBSA Pharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$188
- FREESTYLE LIBRE 3$172
- FreeStyle Libre 2$133
- FreeStyle Libre$123
- TZIELD$119
- REZDIFFRA$118
- RECORLEV$118
How this compares
$4,689 in reported general payments places this provider in the 90th percentile of 56 clinical nurse specialist providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 492 | $587,541 |
| MounjaroTirzepatide | 343 | $430,596 |
| Tresiba Flextouch U-200Insulin Degludec | 144 | $154,709 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 142 | $145,503 |
| JardianceEmpagliflozin | 130 | $138,421 |
| Tresiba Flextouch U-100Insulin Degludec | 161 | $89,838 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 25 | $89,572 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 83 | $72,183 |
| FarxigaDapagliflozin Propanediol | 47 | $50,407 |
| TrulicityDulaglutide | 35 | $45,701 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $45,520 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 35 | $39,878 |
| Humalog Kwikpen U-100Insulin Lispro | 76 | $29,126 |
| JanuviaSitagliptin Phosphate | 24 | $26,566 |
| FiaspInsulin Aspart (Niacinamide) | 34 | $25,647 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $67 | $631,542599 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $357 | $497,445478 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $130 | $142,137143 claims |
| AstraZenecaFarxiga | $38 | $50,40747 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 56 clinical nurse specialist providers in Oklahoma.
Other clinical nurse specialist in Oklahoma City
- Erica MelickOklahoma City$5K
- Cheryl WestOklahoma City$4K
- April MerrillOklahoma City$2K
- Danielle ZacharyOklahoma City$2K
- Heather GrahamOklahoma City$2K
- Amy EberleOklahoma City$1K
- Robin MartinOklahoma City$1K
- Michelle PopeOklahoma City$1K
- Linda PitchfordOklahoma City$929
- Tara SukutOklahoma City$852
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.